InMed Pharmaceuticals (INM) Gains from Investment Securities (2019 - 2026)
InMed Pharmaceuticals (INM) reported Gains from Investment Securities of $13462.0 for Q1 2026, down 78.24% on a YoY basis from $61864.0 in Q1 2025, and down 90.26% quarter-over-quarter from $138150.0 in Q4 2025.
InMed Pharmaceuticals (INM) Gains from Investment Securities (2019 - 2026) Analysis & Trends
InMed Pharmaceuticals has reported Gains from Investment Securities for 8 years, with the latest figure at $13462.0 in Q1 2026.
- For the quarter ending Q1 2026, Gains from Investment Securities fell 78.24% year-over-year to $13462.0; the trailing twelve-month figure through Mar 2026 stood at $13462.0 (down 78.24% YoY), and the FY2025 full-year result was $61410.0, up 111.61% from the prior year.
- Gains from Investment Securities for Q1 2026 stood at $13462.0, down from $138150.0 in the prior quarter.
- The five-year high for Gains from Investment Securities was $678475.0 in Q1 2024, with the low at -$5507.0 in Q3 2022.
- Historically, Gains from Investment Securities has averaged $158725.1 across 5 years, with a median of $64938.0 in 2022.
- Annual changes were most pronounced in 2023 — Gains from Investment Securities soared 1954.6% — and 2025, when it plunged 99.44%.
- InMed Pharmaceuticals' Gains from Investment Securities stood at -$5507.0 in 2022, then soared by 11570.58% to $631685.0 in 2023, then plunged by 95.46% to $28700.0 in 2024, then jumped by 381.36% to $138150.0 in 2025, then slumped by 90.26% to $13462.0 in 2026.
- The last three Gains from Investment Securities figures came in at $13462.0 (Q1 2026), $138150.0 (Q4 2025), and $1054.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.77 Bn | 35.04 Bn | 1.97 Bn |
| 2 | Zoetis | 34.11 Bn | 32.16 Bn | 1.62 Bn |
| 3 | United Therapeutics | 23.68 Bn | 21.53 Bn | 648.10 Mn |
| 4 | Aurora Cannabis | 16.48 Bn | 16.40 Bn | 33.43 Mn |
| 5 | Neurocrine Biosciences | 16.19 Bn | 14.88 Bn | 800.70 Mn |
| 6 | Elanco Animal Health | 11.44 Bn | 11.01 Bn | 785.00 Mn |
| 7 | Alkermes | 7.28 Bn | 6.77 Bn | -116.06 Mn |
| 8 | Lantheus Holdings | 6.48 Bn | 5.98 Bn | 230.92 Mn |
| 9 | Hims & Hers Health | 6.35 Bn | 5.60 Bn | 396.79 Mn |
| 10 | InMed Pharmaceuticals | 5.94 Mn | 696,491.41 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 13,462.00 |
| Mar 31, 2026 | 13,462.00 |
| Dec 31, 2025 | 138,150.00 |
| Dec 31, 2025 | 138,150.00 |
| Sep 30, 2025 | 1,054.00 |
| Sep 30, 2025 | 1,054.00 |
| Mar 31, 2025 | 61,864.00 |
| Mar 31, 2025 | 61,864.00 |
| Dec 31, 2024 | 28,700.00 |
| Dec 31, 2024 | 28,700.00 |
| Sep 30, 2024 | 187,223.00 |
| Sep 30, 2024 | 187,223.00 |
| Mar 31, 2024 | 678,475.00 |
| Mar 31, 2024 | 678,475.00 |
| Dec 31, 2023 | 631,685.00 |
| Dec 31, 2023 | 631,685.00 |
| Sep 30, 2023 | 102,133.00 |
| Sep 30, 2023 | 102,133.00 |
| Sep 30, 2022 | -5,507.00 |
| Sep 30, 2022 | -5,507.00 |